Please login to the form below
Merck and Co/MSD
This page shows the latest Merck and Co/MSD news and features for those working in and with pharma, biotech and healthcare.
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
Merck &Co – known as MSD outside the US and Canada – and Eisai have announced that their immunotherapy combination Keytruda plus Lenvima has been approved in the US to treat endometrial cancer. . ... Patients receiving Merck and Eisai’s treatment
Latest news
-
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Merck &Co – known as MSD outside the US and Canada – has highlighted new data for its blockbuster immunotherapy Keytruda used before and after surgery in high-risk, early-stage triple negative ... In March 2021, the US Food and Drug Administration
-
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
Merck &Co has announced that it will voluntarily withdraw a US Food and Drug Administration (FDA) accelerated approval for Keytruda in third-line stomach cancer. ... In a statement, Merck &Co – known as MSD outside the US and Canada – said that it
-
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
Merck &Co – known as MSD outside the US and Canada – has announced that its PD-1 inhibitor Keytruda plus Eisai’s Lenvima improved outcomes versus Pfizer’s Sutent on a measure ... These results reflect Eisai and Merck’s shared commitment to
-
Merck & Co spinoff Organon launches with the aim of 'improving health outcomes for women'
Merck &Co – known as MSD outside the US and Canada – announced its plans for the women’s health spinoff company last month. ... Merck &Co spinoff company Organon has launched with the aim of making ‘a better and healthier every day for every
-
New trial data for Keytruda in triple-negative breast cancer
Keytruda plus chemotherapy showed significant and meaningful improvement. Merck &Co – known as MSD outside the US and Canada – has revealed additional data for its blockbuster immunotherapy for high-risk, early-stage ... Although detailed results
Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
Merck & Co spinoff Organon launches with the aim of 'improving health outcomes for women'
More from news
Approximately 0 fully matching, plus 69 partially matching documents found.
Latest Intelligence
-
Can protein degraders unlock ‘undruggable’ drug targets?
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
Can protein degraders unlock ‘undruggable’ drug targets?
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Merck & Co appoints Frank Clyburn as president, human health
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global
-
Merck KGaA’s Oschmann elected president of IFPMA
He takes over from Lilly’s John Lechleiter. Global pharma trade body the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has elected Merck KGaA's Stefan Oschmann as its new ... His pharma experience includes an 11-year
-
Merck KGaA shakes up pharma leadership
Johannes Baillou, chairman of the board of partners of Merck, said: “With today's management decisions we strengthen Merck's leadership team and prepare the ground for continuity to reach our ... Oschmann also joined Merck in 2011, having spent the
Merck & Co appoints Frank Clyburn as president, human health
Merck KGaA’s Oschmann elected president of IFPMA
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
-
Digital account director
-
Competitive
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Vertex gains FDA fast track designation for diabetes stem cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Roche appoints Philip Atkinson to new global role
- AZ’s comeback drug cediranib stumbles in phase 3 trial
- MHRA outlines two-year delivery plan with ‘patient first’ focus
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
